Cambridge, MA – 04 February 2021 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announced today that it had been awarded a rescue COVID-19 study. This contract is for a randomized, double-blind, two-part, two-cohort, safety tolerability and efficacy trial of an investigational treatment in COVID-19.
This opportunity was presented to Stiris when the Sponsor received word from the Investigators that the assigned CRO was not working well with the sites and that the sites were considering withdrawing from the study with less than 10 days before the scheduled SIV. Stiris began productive negotiations and is pleased to be on target to ensure the scheduled SIV occurs as planned in February.
“Stiris is always up for a challenge; however, this was a first for us! We had an initial call, contract negotiation and execution, and the first organization meeting all in less than a week. We are literally jumping in with both feet to ensure that this Sponsor meets their critical milestones and we achieve first site initiation as they planned and reported to their Board. We very much look forward to working with this team to accomplish this trial’s objectives and determine if we have a new treatment option in the battle against COVID-19,” said Amanda Carrera, Vice President, Stiris Research Inc.
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact:
Stiris Research Inc.